These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 62062)

  • 1. In vitro uptake of 3H testosterone and its conversion to dihydrotestosterone by prostatic carcinoma and other tissues.
    Prout GR; Kliman B; Daly JJ; Maclaughlin RA; Griffin PP
    J Urol; 1976 Nov; 116(5):603-10. PubMed ID: 62062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered androgen metabolism in metastatic prostate cancer.
    Kliman B; Prout GR; Maclaughlin RA; Daly JJ; Griffin PP
    J Urol; 1978 May; 119(5):623-6. PubMed ID: 77915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of 3H-testosterone to dihydrotestosterone in human hypertrophic prostatic tissue.
    Baranowska B; Zgliczyński S
    Nuklearmedizin; 1979; 18(6):297-9. PubMed ID: 94161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlated biochemical and stereological studies on testosterone metabolism in the stromal and epithelial compartment of human benign prostatic hyperplasia.
    Schweikert HU; Totzauer P; Rohr HP; Bartsch G
    J Urol; 1985 Aug; 134(2):403-7. PubMed ID: 2410636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma.
    Nolten WE; Sholiton LJ; Srivastava LS; Knowles HC; Werk EE
    J Clin Endocrinol Metab; 1976 Dec; 43(6):1226-33. PubMed ID: 1002814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo uptake and metabolism of 3H-testosterone and 3H-5 -dihydrotestosterone by human benign prostatic hypertrophy.
    Becker H; Kaufmann J; Klosterhalfen H; Voigt KD
    Acta Endocrinol (Copenh); 1972 Nov; 71(3):589-99. PubMed ID: 4117573
    [No Abstract]   [Full Text] [Related]  

  • 7. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man.
    Siiteri PK; Wilson JD
    J Clin Invest; 1970 Sep; 49(9):1737-45. PubMed ID: 4194768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testosterone metabolism of fibroblasts grown from prostatic carcinoma, benign prostatic hyperplasia and skin fibroblasts.
    Schweikert HU; Hein HJ; Romijn JC; Schröder FH
    J Urol; 1982 Feb; 127(2):361-7. PubMed ID: 6174738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and action of steroid hormones on human benign prostatic hyperplasia and prostatic carcinoma grown in organ culture.
    Lasnitzki I
    J Steroid Biochem; 1979 Jul; 11(1B):625-30. PubMed ID: 90755
    [No Abstract]   [Full Text] [Related]  

  • 10. Testosterone metabolism in vivo by human prostatic tissue.
    Peeling WB; Pike A; Harper ME; Pierrepoint CG; Griffiths K
    Biochem J; 1970 Nov; 120(2):443-5. PubMed ID: 4099692
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined treatment with the 5 alpha-reductase inhibitor PNU 157706 and the antiandrogen flutamide on the Dunning R3327 prostatic carcinoma in rats.
    Zaccheo T; Giudici D; di Salle E
    Endocr Relat Cancer; 1999 Sep; 6(3):429-35. PubMed ID: 10516856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydrotestosterone in prostatic hypertrophy. II. The formation and content of dihydrotestosterone in the hypertrophic canine prostate and the effect of dihydrotestosterone on prostate growth in the dog.
    Gloyna RE; Siiteri PK; Wilson JD
    J Clin Invest; 1970 Sep; 49(9):1746-53. PubMed ID: 4194769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate tissue androgens: history and current clinical relevance.
    Marks LS; Mostaghel EA; Nelson PS
    Urology; 2008 Aug; 72(2):247-54. PubMed ID: 18502483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone metabolism in prostate; formation of androstan-17-beta-ol-3-one and androst-4-ene-3, 17-dione, and inhibitory effect of natural and synthetic estrogens.
    Shimazaki J; Kurihara H; Ito Y; Shida K
    Gunma J Med Sci; 1965 Dec; 14(4):313-25. PubMed ID: 4162344
    [No Abstract]   [Full Text] [Related]  

  • 15. Testosterone metabolism in benign prostatic hypertrophy. Suppression by diethylstilbestrol and gestonorone capronate.
    Orestano F; Klose K; Rubin A; Knapstein P; Altwein JE
    Invest Urol; 1974 Sep; 12(2):151-6. PubMed ID: 4137236
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
    Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
    Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basis for hormonal management of advanced prostate cancer.
    Geller J
    Cancer; 1993 Feb; 71(3 Suppl):1039-45. PubMed ID: 7679038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinetics of 3H-5 -dihydrotestosterone metabolism in normal men and women and men with prostatic carcinoma; effects of estrogen administration in men.
    Bird CE; Clark AF
    J Clin Endocrinol Metab; 1972 Mar; 34(3):467-72. PubMed ID: 5011250
    [No Abstract]   [Full Text] [Related]  

  • 19. Tissue content of dihydrotestosterone in human prostatic hyperplasis is not supranormal.
    Walsh PC; Hutchins GM; Ewing LL
    J Clin Invest; 1983 Nov; 72(5):1772-7. PubMed ID: 6195192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tamoxifen on the binding and metabolism of testosterone by human prostatic tissue and plasma in vitro.
    Habib FK; Rafati G; Robinson MR; Stitch SR
    J Endocrinol; 1979 Dec; 83(3):369-78. PubMed ID: 94084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.